Top ▲

Follicular lymphoma

GtoPdb Disease Summaries

This section gives an overview of the disease, and where available shows the following:

  • Synonyms: Shows known synonyms for the disease.
  • Description: Gives a basic description/definition of the disease.
  • Database Link: External links to the same disease at the Disease Ontology, OMIM or Orphanet sites.
  • Immunopharmacology comments: General comments about the target's role in immunopharmacology, provided by GtoImmuPdb curators.
  • Associated with: Counts are displayed for the total targets the disease is associated with in GtoPdb. The counts of targets and ligands of immunological relevance associated to the disease are also shown.

More information can be found in the help pages.

✖
Disease ID:1228
Name:Follicular lymphoma
Associated with:0 target
1 immuno-relevant ligand
Description
An indolent non-Hodgkin lymphoma.
Database Links
Disease Ontology: DOID:0050873

Targets

GtoPdb Disease Summaries - Targets

Click on the target name to link to its detailed view page

Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.

If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page

Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.

More information can be found in the help pages.

✖
Key to terms and symbols

No target related data available for Follicular lymphoma

Ligands

GtoPdb Disease Summaries - Ligands

Click ligand name to view ligand summary page

  • Approved: If the ligand is an approved drug this is indicated, along with approval bodies.
  • Immuno: Immuno icon indicates the ligand is immuno-relevant

Click the arrow in the final column to expand comments

  • Immuno Disease Comments: Curatorial comments specifically added as part of GtoImmuPdb. They give more information on the association between the ligand and disease in the context of immunopharmacology.
  • Clinical Use: General clinical comments relating to the ligand and may not necessarily be specific to the disease in question. With hyperlink to more details on the ligand summary pages.
  • Bioactivty Comments: Curatorial comments specifically about the compounds biological activity - with hyperlink to more details on the ligand summary pages.

More information can be found in the help pages.

✖
Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
obinutuzumab
Immuno Disease Comments: Approval is for a combination therapy of obinutuzumab with bendamustine, followed by obinutuzumab monotherapy.
Clinical Use: Initially approved to treat chronic lymphocytic leukemia (CLL) in combination with chemotherapy in patients who have received no prior therapy. In November 2012, this antibody was authorised as an orphan drug by the EMA for the treatment of CLL. Full EMA approval for CLL was granted in July 2014.
In February 2016, the US FDA expanded approval to include treatment of patients with follicular lymphoma (FL) who have relapsed after, or are refractory to, a -containing regimen. This new approval is for a combination therapy of obinutuzumab with , followed by obinutuzumab monotherapy.
In September 2019 the FDA granted Breakthrough Therapy Designation as a treatment for lupus nephritis, a condition for which there is no currently FDA-approved drug. Results from Phase 2 trial NCT02550652 (NOBILITY study) led to this designation. Obinutuzumab (plus standard of care) demonstrated enhanced efficacy compared to placebo plus standard of care in achieving complete renal response (results to be published) [1]. | View clinical data
Bioactivity Comments: In vitro, obinutuzumab induces cell death and antibody-dependent cell-mediated cytotoxicity (ADCC) more effectively than the original type I anti-CD20 antibodies and [2]. In vivo, obinutuzumab induces a strong antitumour effect [2].
However, we have been unable to find affinity data for this antibody from any open access source. | View biological activity

References

Show »

1. Genentech Media. FDA Grants Breakthrough Therapy Designation for Genentech’s Gazyva (Obinutuzumab) in Lupus Nephritis. Accessed on 25/09/2019. Modified on 25/09/2019. Genentech, https://www.gene.com/media/press-releases/14811/2019-09-17/fda-grants-breakthrough-therapy-designat?elqTrackId=8dd752c5464246d2864338e62ba78820&elq=7aed654c4c2d4934a203067e44937351&elqaid=26161&elqat=1&elqCampaignId=10601

2. Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S et al.. (2013) Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther, 12 (10): 2031-42. [PMID:23873847]